- Home
- ATER vs IMRN Comparison
ATER vs IMRN Comparison
Compare ATER & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATER | IMRN |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0M | 5.9M |
| IPO Year | 2019 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ATER | IMRN |
|---|---|---|
| Price | $0.58 | $0.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 63.9K | 19.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,045,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.52 | $0.68 |
| 52 Week High | $3.50 | $2.38 |
Technical Indicators
Market Signals| Indicator | ATER | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 39.48 | 43.19 |
| Support Level | $0.52 | $0.68 |
| Resistance Level | $0.74 | $1.95 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 27.59 | 44.36 |
Price Performance
Historical ComparisonAbout ATER Aterian Inc.
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products and, consumer electronics. It has various owned and operates brands, including HomeLabs, Squatty Potty, Healing Solutions, PurSteam, and others. The company generates revenue through the online sales of various consumer products that are sold online.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.